Europe's TAVR No. 4 Buys Into Mitral Valve Space
Transcatheter aortic valve replacement specialist Symetis has made its maiden acquisition, buying preclinical-stage mitral valve repair firm Middle Peak Medical.
You may also be interested in...
LivaNova Finishes Feasibility Trial Of Transcatheter Mitral Valve, Anticipates 2020 CE Mark
PRELUDE feasibility study of LivaNova's Caisson transseptal transcatheter mitral valve replacement (TMVR) system is complete and the company the INTERLUDE CE Mark trial has begun, the company announced. The company is now working with the US FDA to finalize the protocol for the ENSEMBLE US pivotal trial.
Starts & Stops: Medtronic's TMVR News Closes Big Month For Trial Announcements
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial announcements, initiations, completions, and suspensions each month. This month's edition, covering a long list of device trial updates that occurred between Sept. 24 and Oct. 31, is headlined by Medtronic's APOLLO US pivotal trial of the Intrepid transcatheter mitral valve.
Market Intel: Relentless Rise Of Transcatheter Tech: Heart Valve Repair Turns Back On Open Surgery
The global market for products treating heart valve disease is expected to exceed $8bn by 2021, driven largely by the rising number of elderly patients with cardiovascular disease, obesity and growing prevalence of diabetes. This, in turn, is fueling significant innovation in minimally invasive techniques, particularly in the leading area of transcatheter aortic valve replacement (TAVR), but also in transcatheter mitral valve repair (TMVrep) systems, both of which offer patients quicker recovery times, less discomfort and greater safety compared to traditional surgical heart valve repair and replacement. This feature looks more closely at the competitive landscape and dynamics of these two fast-growing market segments, as well as gives insight into what the users – the physicians – think of these technologies.